Overview
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Eligibility
Inclusion Criteria:
- Histologically confirmed breast cancer;
- Prior or current use of Disitamab vedotin (RC48-ADC);
Exclusion Criteria:
- Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.